
Press Release

HEPTA MEDICAL, the medical device company dedicated to providing an efficient, safe and minimally-invasive thermal ablation therapy for early-stage lung cancer, announced today that the US Patent Office has allowed for publication a non-provisional patent application filed by HEPTA MEDICAL in 2021. This patent covers the design of HEPTA Medical's microwave ablation probe, including its microwave radiometric temperature sensing technology.

"This is our 4th patent family protecting our proprietary temperature sensing technology, but this is the first one filed by the team in 2021, the three other families are licensed patents" comments Thomas Bancel, CEO of HEPTA Medical. *"This marks a major achievement for us, and confirms the uniqueness of our approach in the field of controlled thermal ablation procedures"*.

Based on the date of the priority data, the expected expiration date of this patent is at least until 2039. The related European Patent has already been granted in 2023.

About HEPTA Medical:

HEPTA Medical develops a flexible microwave ablation platform for the minimally-invasive treatment of early-stage lung cancer patients. Its incision-less technology can deliver thermal energy through the airway.

HEPTA Medical's microwave ablation probe is equipped with a proprietary patented temperature sensor enabling to monitor and control the growth of the ablation zone during the procedure. HEPTA Medical brings thermal ablation a step further in achieving safe and efficient ablation treatments.

HEPTA Medical was founded in 2019 out of MD Start – the medical device incubator of Sofinnova Partners. The company is based in Suresnes, France.

Contact:

Dr. Thomas BANCEL, CEO: thomas@heptamed.com

HEPTA MEDICAL

Société par actions simplifiée au capital de 4.813€
Siège social : 5-11 rue Gardenat Lapostol, Chez DocCity, 92150 Suresnes
833 861 255 RCS Paris B